Kairos Pharma to Present at LD Micro Invitational, Highlighting Clinical Progress in Oncology

Kairos Pharma Ltd. (NYSE American: KAPA) announced that its CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles. The presentation will provide an update on the company’s clinical program and partnering activities, underscoring the importance of this event for investor awareness and potential strategic collaborations.

The company, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. However, the ongoing trials represent critical steps toward potential approval.

The presentation at the LD Micro Invitational is significant because it provides a platform for Kairos Pharma to engage with the investment community and highlight its progress. This event is known for attracting institutional investors, analysts, and industry experts, offering companies like Kairos Pharma the opportunity to showcase their science and business development efforts. For investors, the presentation will offer insights into the company's clinical milestones and future direction.

Kairos Pharma’s focus on CD105 is notable because this protein is increasingly recognized as a key mediator of resistance in various cancers. By targeting CD105, ENV-105 could potentially enhance the efficacy of existing treatments, addressing a major challenge in oncology. The company’s approach of using structural biology to design therapeutics is innovative and may lead to more effective treatments with fewer side effects.

For more information, the full press release can be viewed at https://ibn.fm/g3aQY. Additionally, the latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.